Phase 1 study of ZV0203, a first in class pertuzumab ADC, in patients with HER2 positive advanced solid tumors.

Kadcyla (ado-trastuzumab emtansine) - Roche

ADC2122 - ZovaBio, Adcoris

Perjeta (pertuzumab) - Roche

Zhenwei Miao; Fengjuan Lin; Xi Rao; Yong Huang; Feng Wang; Yao LU; Xiuying Huang; Yunsheng Huang

Apr 25, 2024